• WebBanner_688x217_CoverPhoto_r1-01

  • slide_prepvideos

  • slide_adaywithhiv

  • Slideshow_knowmorehepc

  • Slideshow_hivhealthreform

Project Inform launches new educational videos on PrEP

post_prepvideos

Project Inform announced today the release of four new educational videos on the topic of PrEP, or Pre-Exposure Prophylaxis. PrEP is a new prevention tool that currently involves taking an HIV medication daily by an HIV-negative person to help prevent getting the virus. In July 2012,…Read More

Certain people with HIV may be at higher risk for cryptococcal disease

post_crypto

In results from a MACS study published online August 27, 2013 by the American Society of Microbiology, some people living with HIV face a 20-times higher risk for the fungal disease Cryptococcal neoformans, or “crypto”. This is due to the presence of a gene that expresses…Read More

FDA approves the first genotype test for hepatitis C

post_hcvgenotype

In June 2013, the US Food & Drug Administration (FDA) approved the first test for detecting the various genotypes of hepatitis C. This blood/serum test should only be used for those diagnosed with chronic hepatitis C, and not for routine screening of the virus. The Abbott…Read More

New results suggest exercise may reduce neuro-cognitive impairment in HIV

post_hivbrain

In an article published in the Journal of Neurovirology (June 2013), results from a small study suggest that physical exercise may reduce neuro-cognitive impairment and improve working memory as well as speed of processing information in HIV-positive people. From 2007-2011, the small study included 83 people…Read More

Slightly higher risk of AIDS-related conditions seen at 500–750 CD4s

post_cd4count

In an article published online ahead of print in Clinical Infectious Diseases, results from the large COHERE study show that HIV-positive people with 500-750 CD4s have a higher rate of AIDS-defining illnesses (ADI), compared to those with CD4s above 750 cells. Although the comparison is statistically…Read More

New two-drug regimen cures hepatitis C in difficult-to-treat cases

post_sofosbuvirribavirin

In an article published in the Journal of the American Medical Association, the new 2-drug regimen of sofosbuvir + ribavirin cured a little more than 2/3 of patients with difficult-to-treat hepatitis C. Characteristics in this study that related to being “difficult to treat” included having genotype…Read More

“A Day With HIV” campaign seeks to de-stigmatize HIV

post_adaywithhiv

Whether you’re HIV-positive or HIV-negative, we’re all affected by HIV. HIV stigma can discourage people from getting tested for HIV, just as it can make others fear disclosing their status to friends and loved ones. Positively Aware, the HIV magazine published by Test Positive Aware Network in…Read More